Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials

Sungkyoung Kim
Wenping Ding
Lian Zhang
Wei Tian
Siyu Chen

Department of Oncology, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China

Abstract: Angiogenesis is an integral process in carcinogenesis, and molecular inhibitors of angiogenic factors are currently being tested as treatments for cancer. Sunitinib is an oral multitargeted tyrosine-kinase inhibitor that blocks activation through the stem cell-factor receptor (Kit) and platelet-derived growth-factor receptor. Sunitinib has shown potent antitumor activity against several solid tumors, including renal cell carcinoma, gastrointestinal stromal tumors, and neuroendocrine tumors in several Phase II/III trials. Recently, sunitinib has been used to treat other solid cancers, such as lung cancer, pancreatic cancer, chondrosarcoma, esophageal cancer, bladder cancer, glioma, and aggressive fibromatosis, and also showed potential efficacy in progression-free survival and overall survival. In this review, we examine the efficacy of sunitinib as a molecular-targeted therapy in patients with different types of solid cancers.

Keywords: anti-angiogenic therapy, molecular-targeted therapy, tumor, antitumor activity

Introduction

Sunitinib (Sutent®; Pfizer, New York, NY, USA) is a multitargeted tyrosine-kinase inhibitor (TKI) with activity against the stem cell-factor receptor (Kit) and platelet-derived growth-factor receptor (PDGFR), vascular endothelial growth-factor receptor (VEGFR), glial cell line-derived neurotrophic factor receptor (rearranged during transfection [RET]), colony-stimulating factor-1 receptor (CSF1R), and Fms-like tyrosine kinase-3 receptor (FLT3).1,2 Several clinical trials have demonstrated that sunitinib has an objective response rate (ORR) as high as 40% in the treatment of metastatic renal cell carcinoma (mRCC), and have recommended sunitinib as a first-line therapeutic option.3 Another TKI, imatinib, is used in first-line therapy for unresectable and metastatic gastrointestinal stromal tumor (GIST), but in patients who are intolerant to imatinib therapy, sunitinib is recommended as the second-line option in GIST. Results from a Phase I/II study showed that sunitinib had promising clinical activity in patients with imatinib-resistant GIST.4 Furthermore, sunitinib has potential antitumor activity in various malignant tumors, such as lung cancer, pancreatic cancer, pancreatic neuroendocrine tumor (PNET), esophageal cancer, bladder cancer, glioma, and sarcoma.5–10

This review examines the antitumor efficacy of sunitinib in solid cancers, and summarizes both its preclinical activity and clinical development, including early and latest clinical trials. We discuss the mechanism of sunitinib’s antiangiogenic activity and drug-resistance and toxicity studies. We conclude with an examination of the role of sunitinib as a single-agent therapy, combination with chemotherapy or radiotherapy, and its future directions.
**Mechanism of action**

Sunitinib is a multitargeted TKI that acts on VEGFR, PDGFR, Kit, FLT3, RET, and CSF1R, and its antitumor activity has been demonstrated in various tumors. The antioncogenic mechanism of sunitinib is based upon a hypothesis derived from preclinical data of its transition of malignancy to alternative tumor-promoting pathways and its ability to upregulate alternative proangiogenic factors. Sunitinib is characterized by an oral indolin-2-one structural analog, which inhibits multiple receptor tyrosine kinases (RTKs) and exerts potent antiangiogenesis and antitumor effects. The spectrum of kinases inhibited by sunitinib includes VEGFR1, -2, and -3, PDGFRα, PDGFRβ, Kit, FLT3, RET, and CSF1R. Sunitinib potently and specifically inhibits these targets in biochemical and cell-based assays. Previous studies have shown that sunitinib has the best pharmacologic and binding potency profile for VEGFR and PDGFR at the biochemical and cellular levels. The phosphorylated receptor acts as a docking domain for intracellular adaptors that lead to the activation of a cascade of intracellular signal-transduction mediators, eventually leading to deoxyribonucleic acid synthesis, cell division, growth, proliferation, and migration. The Kit TKI sunitinib has shown a promising clinical profile for mastocytosis/mast cell leukemia, germ cell cancers, small-cell lung cancer, GISTs, acute myelogenous leukemia, neuroblastoma, melanoma, ovarian carcinoma, and breast carcinoma. In GIST, sunitinib against wild-type and exon 9-mutant Kit was superior to that of imatinib in vitro, whereas both drugs exhibited similar potency against Kit exon-11 mutant kinases.

**CSF1R** is expressed on monocytic progenitors, binds with macrophage CSF to stimulate osteoclasts and enhances the osteolytic activity of osteoclasts. CSF1R expression has been reported in breast, ovarian, and endometrial cancers, and associated with poor prognosis and invasive potential. Moreover, CSF1R appears to be an attractive target for the treatment of bone metastasis. FLT3 is another TKI that when mutated may lead to the development of a specific type of leukemia, known as acute myeloid leukemia. Furthermore, sunitinib targets mutant RET, which is involved in the multiple endocrine neoplasia types 2A and 2B autosomal-dominant syndromes, familial medullary thyroid carcinoma, and perhaps sporadic NETs.

**Sunitinib in solid cancers**

**Single agent as multitargeted TKIs**

Many clinical trials have shown that sunitinib is a first-line therapy for mRCC and has reasonable ORR, PFS, and OS. In a retrospective study of sunitinib for advanced clear-cell RCC (n=76), median PFS was 7.2 months (95% confidence interval [CI] 4.7–9.7 months) and median OS was 22.8 months (95% CI 18.7–26.9 months). The disease-control rate, including complete response (CR), partial response (PR), and stable disease (SD) was 84.2% (95% CI 74.0%–91.6%). In non-clear-cell RCC (n=10), PR was 10%, median PFS was 5.1 months (95% CI 4.2–6.0 months), and median OS was 9.0 months (95% CI 0.5–17.4 months). In another series of retrospective studies conducted by Zama et al, the initial sunitinib treatment (n=24) produced a PR of 65% and a median PFS of 13.7 months. Furthermore, a recent study reported that sunitinib was superior to interferon (IFN)-α in PFS and ORR. A Phase III trial (n=750) measured health-related quality of life and compared sunitinib (n=375) with IFNα (n=375) in patients with mRCC, and showed that the health-related quality of life in patients treated with sunitinib was better than patients treated with IFNα. This means that sunitinib is better in terms of tolerated efficacy and safety than IFNα. However, in patients with untreated brain metastases of mRCC, sunitinib cannot be recommended as a valid option, due to its limited efficacy in brain metastases. Notably, no neurologic complication has been observed with sunitinib therapy. The results of other clinical trials for RCC are summarized in Table 1.

The effective systemic therapy for GIST is imatinib and sunitinib, routinely. As the first-line systemic treatment in patients with metastatic GIST, imatinib induces regression or stabilization in over 80% of patients, and sunitinib can achieve responses in patients refractory to imatinib. A retrospective study conducted to evaluate the effect of sunitinib in GIST patients showed that sunitinib had a clinical benefit (including CR, PR, and SD) of 65.2% after 6 months of administration. Table 2 shows the clinical efficacy of sunitinib for treatment in patients with refractory GIST or who are intolerant to imatinib.

Single-agent sunitinib has also demonstrated antitumor activity in several preclinical breast cancer models, both alone and in combination with chemotherapy. A Phase II trial demonstrated that patients with refractory, late-stage metastatic breast cancer receiving sunitinib as monotherapy had PR of 11% and SD of 5%. The median time to progression (TTP) and OS were 10 and 38 weeks, respectively, in this study. However, the efficacy of sunitinib monotherapy was inferior to standard care with chemotherapy in advanced triple-negative breast cancer that lacks expression of the estrogen receptor, progesterone receptor and human epidermal growth-factor receptor 2 (Table 3).
A Phase II study showed the limited efficacy of sunitinib in patients with advanced esophageal cancer, and over half of patients discontinued due to disease progression and toxicity. In patients with aggressive fibromatoses, sunitinib showed potential antitumor activity and was relatively well tolerated. In previous clinical trials for advanced hepatocellular carcinoma (HCC), sunitinib failed its primary OS end point, but PFS and TTP results were similar between sunitinib and sorafenib. Sunitinib was associated with more frequent toxicities versus sorafenib. After sorafenib-treatment failure in advanced hepatocellular carcinoma, sunitinib had substantial antitumor activity with a manageable toxicity profile.

Several Phase II trials have shown limited efficacy of PR and SD in metastatic thyroid cancer. A retrospective study showed that PR was obtained in 55.5% of patients, median PFS and OS were 21 and 21 months, respectively, and confirmed that sunitinib is a potential useful option for the treatment advanced thyroid cancer. In another Phase II study, sunitinib was administered daily on a continuous basis, and there was 3% CR, 28% PR, and 46% with SD. PD was observed at 17%, and median TTP was 12.8 months.

### Table 1 Clinical trials of SU (25–50 mg/day, orally, days 1–14, every 21 days) as a single agent in mRCC (2010–2013)

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Patients</th>
<th>Therapy</th>
<th>Results (RECIST)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mORR (%)</td>
</tr>
<tr>
<td>Zama et al</td>
<td>I</td>
<td>23</td>
<td>Initial SU</td>
<td>65 (PR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>23</td>
<td>Rechallenge</td>
<td>21 (PR)</td>
</tr>
<tr>
<td>Keizman et al</td>
<td>I</td>
<td>44</td>
<td>SU</td>
<td>86 (PR + SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>83</td>
<td>Nonusers</td>
<td>72 (PR + SD)</td>
</tr>
<tr>
<td>Molina et al</td>
<td>II</td>
<td>23</td>
<td>All</td>
<td>4 (PR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>8</td>
<td>Papillary</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>15</td>
<td>Non-clear cell</td>
<td>4 (PR)</td>
</tr>
<tr>
<td>Rini et al</td>
<td>III</td>
<td>442</td>
<td>SBP: $\geq 140$ mmHg</td>
<td>54.8 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>92</td>
<td>$&lt;140$ mmHg</td>
<td>8.7 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>363</td>
<td>DBP: $\geq 90$ mmHg</td>
<td>57.3 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>171</td>
<td>$&lt;90$ mmHg</td>
<td>24.6 (CR + PR)</td>
</tr>
<tr>
<td>van der et al</td>
<td>I</td>
<td>55</td>
<td>RECIST</td>
<td>13 (PR)</td>
</tr>
<tr>
<td>Veldt et al</td>
<td>I</td>
<td>55</td>
<td>Choi criteria</td>
<td>65 (PR)</td>
</tr>
<tr>
<td>Yoo et al</td>
<td>I</td>
<td>65</td>
<td>SU</td>
<td>43 (PR)</td>
</tr>
<tr>
<td>Molina et al</td>
<td>II</td>
<td>20</td>
<td>SU + everolimus$^a$</td>
<td>25 (PR)</td>
</tr>
<tr>
<td>Keizman et al</td>
<td>II</td>
<td>35</td>
<td>SU + bisphosphonates</td>
<td>86 (PR + SD)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SU + nonbisphosphonate</td>
<td>71 (PR + SD)</td>
</tr>
</tbody>
</table>

**Notes:** $^a$Sunitinib-induced hypertension with antitumor efficacy; $^b$everolimus 2.5–5 mg daily or 20–30 mg weekly.

**Abbreviations:** mRCC, metastatic renal cell carcinoma; mORR, median objective response rate; CR, complete response; PR, partial response; mSD, median stable disease; mPD, median progressive disease; mTTP, median time to progression; mPFS, median progression-free survival; mOS, median overall survival; mRCC, metastatic renal cell carcinoma; RECIST, Response Evaluation Criteria in Solid Tumors; SU, sunitinib; SBP, systolic blood pressure; DBP, diastolic blood pressure.

### Table 2 Clinical studies of SU (25–50 mg/day, orally, days 1–14, every 21 days) as a single agent in GIST (2010–2013)

<table>
<thead>
<tr>
<th>Study</th>
<th>Phase</th>
<th>Patients</th>
<th>Therapy</th>
<th>Results (RECIST)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mORR (%)</td>
</tr>
<tr>
<td>Younus et al</td>
<td>III</td>
<td>207</td>
<td>SU</td>
<td>7 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>105</td>
<td>Placebo</td>
<td>0 (CR + PR)</td>
</tr>
<tr>
<td>Rutkowski et al</td>
<td>I</td>
<td>137</td>
<td>SU</td>
<td>15 (PR)</td>
</tr>
<tr>
<td>Chen et al</td>
<td>I</td>
<td>23</td>
<td>SU</td>
<td>26.1 (CR + PR)</td>
</tr>
<tr>
<td>Italiano et al</td>
<td>I</td>
<td>223</td>
<td>SU</td>
<td>–</td>
</tr>
<tr>
<td>Bertucci et al</td>
<td>III</td>
<td>58</td>
<td>After 1 year</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>50</td>
<td>After 3 years</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td></td>
<td>27</td>
<td>After 5 years of imatinib</td>
<td>–</td>
</tr>
<tr>
<td>Matsumoto et al</td>
<td>II</td>
<td>80</td>
<td>SU</td>
<td>5.6 (PR)</td>
</tr>
</tbody>
</table>

**Note:** $^a$Randomized in imatinib-refractory.

**Abbreviations:** GIST, gastrointestinal stromal tumor; mORR, median objective response rate; CR, complete response; PR, partial response; mSD, median stable disease; mPD, median progressive disease; mTTP, median time to progression; mPFS, median progression-free survival; mOS, median overall survival; RECIST, Response Evaluation Criteria in Solid Tumors; SU, sunitinib.
### Table 3: Current clinical trials of SU (25–50 mg/day, orally, days 1–14, every 21 days) for solid cancers (2011–2013)

<table>
<thead>
<tr>
<th>Disease</th>
<th>Study (Phase)</th>
<th>Patients</th>
<th>Therapy</th>
<th>Results (RECISt)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>mORR (%) (CR or PR)</td>
</tr>
<tr>
<td>Single agent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABC</td>
<td>Curigliano et al (ii)</td>
<td>113</td>
<td>SU</td>
<td>3 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td>Standard of care with chemotherapy</td>
<td>104</td>
<td>SU</td>
<td>7 (CR + PR)</td>
</tr>
<tr>
<td>AEC</td>
<td>Knox et al (ii)</td>
<td>70</td>
<td>As adjuvant therapy</td>
<td>–</td>
</tr>
<tr>
<td>AF</td>
<td>Jo et al (ii)</td>
<td>19</td>
<td>SU</td>
<td>26.3 (PR)</td>
</tr>
<tr>
<td>AHC</td>
<td>Cheng et al (iii)</td>
<td>529</td>
<td>SU 400 mg/day, twice a day</td>
<td>–</td>
</tr>
<tr>
<td>MHC</td>
<td>Yau et al (ii)</td>
<td>38</td>
<td>SU</td>
<td>6 (PR)</td>
</tr>
<tr>
<td>MTC</td>
<td>Pasqualetti et al (i)</td>
<td>9</td>
<td>SU</td>
<td>55.5 (PR)</td>
</tr>
<tr>
<td>MUM</td>
<td>Sacco et al (ii)</td>
<td>74</td>
<td>SU</td>
<td>0 (PR)</td>
</tr>
<tr>
<td>NSCLC</td>
<td>Reynolds et al (i)</td>
<td>63</td>
<td>SU</td>
<td>6.7 (CR + PR)</td>
</tr>
<tr>
<td>Heist et al (ii)</td>
<td>41</td>
<td>SU</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pemetrexed + SU</td>
<td>41</td>
<td>Pemetrexed</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Pemetrexed</td>
<td>46</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>SCLC</td>
<td>Han et al (i)</td>
<td>25</td>
<td>SU</td>
<td>9 (CR + PR)</td>
</tr>
<tr>
<td>PNET</td>
<td>Raymond et al (iii)</td>
<td>86</td>
<td>SU</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>85</td>
<td>Placebo</td>
<td>–</td>
</tr>
<tr>
<td>Combination with chemotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGC</td>
<td>Lee et al (i)</td>
<td>28</td>
<td>SU + XP</td>
<td>46.7 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td>SU + XELOX</td>
<td>48</td>
<td>45.5 (CR + PR)</td>
<td>–</td>
</tr>
<tr>
<td>ABC</td>
<td>Robert et al (iii)</td>
<td>242</td>
<td>SU + paclitaxel</td>
<td>78</td>
</tr>
<tr>
<td></td>
<td>Bevacizumab + paclitaxel</td>
<td>243</td>
<td>78</td>
<td>–</td>
</tr>
<tr>
<td>AEC</td>
<td>Moehler et al (ii)</td>
<td>45</td>
<td>FOLFIRI + SU</td>
<td>20 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td>FOLFIRI + placebo</td>
<td>46</td>
<td>29 (CR + PR)</td>
<td>–</td>
</tr>
<tr>
<td>Schmitt et al (ii)</td>
<td>28</td>
<td>SU + paclitaxel</td>
<td>11 (CR + PR)</td>
<td>–</td>
</tr>
<tr>
<td>APC</td>
<td>Richly et al (ii)</td>
<td>113</td>
<td>Gemcitabine + SU</td>
<td>7.1 (ORR + SD)</td>
</tr>
<tr>
<td></td>
<td>Gemcitabine</td>
<td>6.1 (ORR + SD)</td>
<td>3.5</td>
<td>3.3</td>
</tr>
<tr>
<td>Gioma¹</td>
<td>Duerinck et al (ii)</td>
<td>13</td>
<td>SU + lomustine</td>
<td>15 (CR + PR)</td>
</tr>
<tr>
<td>MPM</td>
<td>Laurie et al (ii)</td>
<td>17</td>
<td>Prechemotherapy</td>
<td>0 (CR + PR)</td>
</tr>
<tr>
<td></td>
<td>Previously untreated</td>
<td>18</td>
<td>5.5 (CR + PR)</td>
<td>55.5</td>
</tr>
<tr>
<td>MUC</td>
<td>Galsky et al (i)</td>
<td>36</td>
<td>SU + gemcitabine + cisplatin</td>
<td>49 (CR + PR)</td>
</tr>
<tr>
<td>SCLC</td>
<td>Ready et al (ii)</td>
<td>44</td>
<td>Chemotherapy + SU</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Chemotherapy + placebo</td>
<td>41</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Notes: ¹MHC after sorafenib failure; ²dacarbazine 1,000 mg/m² every 21 days; ³capcitabine + cisplatin (XP); ⁴capcitabine + oxaliplatin (XELOX); ⁵gemcitabine 1,000 mg/m² days 1, 8, 15 every 28 days; ⁶glioma temozolomide-refractory; ⁷S/fluorouracil+irinotecan+leucovorin (FOLFIRI).

Abbreviations: ABC, advanced breast cancer; AOC, advanced gastric cancer; AEC, advanced esophageal cancer; AF, aggressive fibromatosis; AHC, advanced hepatocellular carcinoma; APC, advanced pancreatic cancer; MHC, metastatic hepato-cellular carcinoma; MIBC, muscle-invasive bladder cancer; MMP, malignant pleural mesothelioma; MTC, metastatic thyroid cancer; MUC, metastatic urothelial carcinoma; MUM, metastatic uveal melanoma; NSCLC, non-small-cell lung cancer; PNET, pancreatic neuroendocrine tumor; SCLC, small-cell lung cancer; mORR, median objective response rate; CR, complete response; PR, partial response; mSD, median stable disease; mPD, median progressive disease; mTTP, median time to progression; mPFS, median progression-free survival; mOS, median overall survival; RECISt, Response Evaluation Criteria in Solid Tumors; SU, sunitinib.

However, sunitinib, as first-line therapy in metastatic uveal melanoma, did not have significant clinical activity.⁴⁹,⁵⁰

In randomized Phase II trials, sunitinib for the treatment of non-small-cell lung cancer (NSCLC) showed acceptable disease-control response and quality of life improved.⁵¹ However, most patients with SCLC were unable to tolerate the treatment of sunitinib with short PFS (Table 3).⁵²

A study suggested that sunitinib on a continuous daily dosing schedule showed anti-tumor activity in patients with unresectable, well-differentiated PNET.⁵³ A Phase II study showed that the clinical benefit rate was 75%, ORR was 50%, and PFS was 91% at 6 months and 71% at 12 months.⁵⁴ Raymond et al reported that single-agent sunitinib had a 12.6-month median PFS.⁵⁵ In an early study, sunitinib significantly reduced the growth of castration-resistant prostate cancer and decreased prostate-specific antigen levels.⁵⁶ A Phase I/II trial in metastatic castration-resistant prostate cancer demonstrated that nine of 18 patients exhibited...
prostate-specific antigen responses of ≥50%, and five of 13 manifested partial radiographic responses. Moreover, in patients with docetaxel-resistant metastatic prostate cancer, sunitinib showed a 12-week PFS of 79%.36

Sunitinib combined with chemotherapy
Many Phase I/II studies of sunitinib in combination with chemotherapy have shown activity and manageable toxicities. However, some Phase III studies have been terminated prematurely or halted due to futility.40,66 In advanced gastric cancer, a Phase I study showed that sunitinib combined with capecitabine/oxaliplatin had an acceptable safety profile over sunitinib combined with capecitabine/cisplatin.53 However, in advanced breast cancer, the sunitinib–paclitaxel regimen was clinically inferior to the bevacizumab–paclitaxel regimen.55 The addition of sunitinib to chemotherapy has yet to demonstrate a significant PFS or OS advantage in patients with advanced esophageal cancer. Comparison of treatment with the FOLFIRI (irinotecan, leucovorin, and fluorouracil) regimen plus sunitinib versus FOLFIRI alone in patients with advanced chemotherapy-refractory esophagealgastric cancer, showed that sunitinib added to FOLFIRI increased hematotoxicity and did not improve ORR or PFS in chemotherapy-resistant patients.59

In advanced pancreatic cancer, the combination of gemcitabine plus sunitinib did not improve PFS compared to gemcitabine alone.61 Phase I/II studies on sunitinib treatment in recurrent malignant glioma have shown that the combination of sunitinib and lomustine or irinotecan has limited antitumor activity and acceptable toxicity.52,63 Sunitinib also has limited activity in malignant pleural mesothelioma, and the response rate was superior to previously cisplatin-based treated patient.64 The efficacy of sunitinib in patients with relapsed or refractory lung cancer is shown in Table 3. In NSCLC, sunitinib had an inferior toxicity profile to pemetrexed, and OS was significantly better with pemetrexed alone compared to sunitinib-containing arms, with pemetrexed plus sunitinib performing worse for OS.52 Sunitinib administration after chemotherapy for extensive-stage SCLC improved PFS, but there was no significant trend toward improved OS.66

Sunitinib combined with radiotherapy
In chondrosarcoma, sunitinib is beneficial, and may be safely combined with proton-beam radiation therapy.57 Sunitinib concurrent with stereotactic radiation resulted CR and PR of 42% and 17%, respectively, and 28% patients had SD. A Phase I/II trial was conducted by Kao et al,68 in which 46 patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated with 37.5 mg sunitinib (days 1–28) and stereotactic body-radiation therapy of 50 Gy (days 8–12 and 15–19). Local control and distant control were 75% and 40%, and PFS and OS 34% and 29%, respectively. This study supported the belief that patients with kidney and prostate primary tumors are associated with significantly improved OS.

Challenges for several cancers
The question of whether sunitinib-induced apoptosis is associated with the induction of Bim or downregulation of Mcl-1 in some colon cancer cell lines has been tested. In addition, a recent study demonstrated that sunitinib induces the p53-upregulated modulator of apoptosis (PUMA), which plays an essential role in p53-dependent and -independent apoptosis in human cancer cells and mice, but its expression is independent of p53 in colon cancer cells. Moreover, a number of more selective VEGFR inhibitors were also found to induce PUMA and apoptosis in colon cancer cells, supporting the non-angiogenic role of anti-VEGFR therapies.69,70

The number of circulating endothelial cells may be useful to predict benefit from maintenance sunitinib therapy. A Phase II study of sunitinib in high-risk patients with uveal melanoma is ongoing, and preliminary data have shown that PFS and OS rates at 2 years were 70% and 100%, respectively.50 A randomized Phase II study evaluated the efficacy of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.71 A Phase II trial of sunitinib in metastatic non-clear RCC is ongoing to evaluate the efficacy of sunitinib compared with everolimus.72

Resistance of sunitinib
The development of sunitinib resistance is accompanied by evasion of antiangiogenic effects and by increased expression of tumor-derived interleukin (IL)-8.73 IL-8 expression was elevated in human RCC tumors with intrinsic resistance to sunitinib therapy, indicating that IL-8 levels may serve as a predictive biomarker for clinical response to sunitinib.74 Obviously, IL-8 plays an important role in the resistance of RCC to sunitinib, and suggests that IL-8 may potentially serve as both a therapeutic target for the treatment of sunitinib-resistant RCC and as a clinical biomarker for both acquired and intrinsic sunitinib resistance. The best marker gene, AMFR, is highly downregulated in sunitinib-sensitive patients. The AMFR gene is associated with angiogenesis and tumor cell motility, and its identification may improve outcome prediction and improve our understanding of the mechanisms of
Resistance. Furthermore, Sato et al reported that the extracellular matrix metalloproteinase inducer (EMMPRIN) plays an important role in tumor progression and sunitinib resistance in RCC. EMMPRIN is highly expressed in human RCC cells, and it plays an important role in their angiogenesis and aggressiveness both in vitro and in vivo. Further studies are required to confirm that targeting EMMPRIN in RCC inhibits tumor angiogenesis, progression, and resistance to TKIs and mammalian target-of-rapamycin inhibitors.

**Toxicity of sunitinib**

A recent study suggested that grade 3–4 clinical TKI-related toxicities, namely digestive, cardiac, dermatologic, and asthenia, are associated with a significant improvement of OS. Several studies reported that the occurrence of overall grade 3–4 toxicities was significantly associated with age, body surface, and sex. Another study reported that the most common toxicities experienced at both initial treatment and rechallenge were fatigue, diarrhea, and hand–foot syndrome. A retrospective study showed that stomatitis (63.2%) and diarrhea (60.5%) were the most commonly reported dose-related adverse events. In mRCC (n=132), the most common adverse events were stomatitis (66.7%), fatigue (52.3%), hand–foot syndrome (49.2%), and anorexia (48.5%). Moreover, the most frequent laboratory abnormality was thrombocytopenia (75%), and 37.8% of patients experienced grade 3 or 4 thrombocytopenia. Other common laboratory abnormalities included increased serum creatinine (75.6%) and elevated alanine aminotransferase (53.5%). Chen et al reported that sunitinib-induced hypothyroidism was observed as a side effect in 12% of GIST patients. The molecular mechanisms of sunitinib-induced hypothyroidism are currently unknown, but one possible mechanism may be via inhibition of VEGFR and/or PDGFR in the thyroid tissue.

**Discussion**

Since it is a multitargeted TKI, sunitinib’s main mechanism of action is through inhibition of tumor angiogenesis, but it also has antiproliferative and apoptotic effects on diverse tumor types. Sunitinib exerts its activity as a competitive inhibitor of the catalytic activity of a group of strictly related RTKs: VEGFR1, -2, and -3, PDGFR-α and -β, Kit, CSF1R, FLT3, and the RTK encoded by the RET proto-oncogene. Sunitinib exerts potent and specific inhibition of these targets in biochemical and cell-based assays. In vitro, sunitinib inhibited VEGF-dependent proliferation and migration of human umbilical endothelial cells and disrupted capillary tube formation, and in vivo models of cancer angiogenesis, sunitinib decreased tumor-microvessel density, blocked vascularization in the vascular window tumor model, and decreased the metastatic potential of several cancers, such as Lewis lung cancer. Sunitinib inhibited the proliferation of human cancer cells induced by VEGF, Kit, and PDGF, while inducing apoptosis in human umbilical endothelial cells in an in vitro study. Preclinical studies suggest that plasma concentrations in the range of 50–100 ng/mL inhibited target activation. In vivo studies, sunitinib exerted significant antitumor activity in xenograft models from numerous tumor types, including renal, colon, breast, lung, melanoma, and epidermoid carcinoma, with once-daily dosing.

We summarized the clinical response of sunitinib, as shown in Tables 1–3. Sunitinib was generally established as a first-line therapy in advanced RCC and second-line therapy in GISTs after disease progression or intolerance to imatinib therapy. Recent clinical trials have reported that sunitinib has strong anticancer activity in PNET and has potential response in other cancers, since VEGF levels are highly correlated with the clinical output of well-vascularized tumors. Clinical trials have shown that sunitinib can be administrated as a single agent or in combination with chemotherapy or radiotherapy in different types of advanced cancers. Most clinical trials have suggested that sunitinib is efficacious, especially in mRCC and GIST, as a single agent. The benefits of sunitinib have also been shown in SCLC, NSCLC, and advanced esophageal cancer, and in combination therapy in urinary cancer. Much of our experience with sunitinib has been with the maximum tolerated dose of 75 mg and the recommended dose of 50 mg/day, 4 weeks on, 2 weeks off schedule in solid cancers.

Our review has demonstrated that sunitinib has a significant, beneficial response in mRCC and GIST. A beneficial response has also been shown in SCLC, breast cancer, thyroid cancer, chondrosarcoma, and other cancers. There are different responses in different types of cancers (Figure 1), and previous studies have supported the belief that relative factors may be associated with the clinical response. These studies have suggested some predictive biomarkers, such as an increase in circulating endothelial cells and smoking, but body mass index, diabetes mellitus, and pretherapy hypertension were not found to be associated with outcome. It is apparent that there needs to be a definition of the optimal biologic dose of antiangiogenic agents used as treatment for mRCC, GIST, and PNET. The combination of sunitinib and chemotherapy can improve OS in several solid cancers, such as SCLC and advanced esophageal cancer. However, sunitinib has failed as a treatment for NSCLC, metastatic breast cancer, and advanced pancreatic cancer. Although many trials have suggested that
sunitinib represents a major therapeutic advancement in the treatment of mRCC, the best response to multikinase inhibitors is only temporary disease stabilization. For this purpose, a Phase II study was conducted to evaluate the efficacy of erlotinib (150 mg/day, orally) and sirolimus (6 mg orally on day 8, followed by 2 mg daily) in mRCC patients after failure with sunitinib or sorafenib (n = 25). The results showed that median PFS for these patients was 12 weeks (95% CI 5.9–18.1) and median OS 40 weeks (95% CI 0–85.7). SD of less than 6 months was noted in 21.8% (95% CI 4.9%–38.6%) of patients. No confirmed CR or PR was observed.

Conclusion
For now, further developmental and investigational studies are necessary to demonstrate the mechanism of drug-resistance, to aid in the development of advanced clinical trials, and to design more effective monoclonal antibodies for the treatment of sunitinib-refractory cancers.

Acknowledgments
This work was supported by the National Natural Science Foundation of China (81274142), the Natural Science Foundation of Science and Technology Commission of Shanghai Municipality (11ZR1423400), and the Key Project of Shanghai Municipal Education Commission (07zz43).

Disclosure
The authors declare no conflicts of interest in this work.

References
tumour perfusion assessed by 15O-water-PET imaging during treatment
with sunitinib malate in patients with advanced malignancies. 
factors of sunitinib therapy in advanced gastrointestinal stromal tumors
(GIST) after imatinib failure – one institution study. BMC Cancer. 
10. Delbaldo C, Faivre S, Dreyer C, Raymond E. Sunitinib in advanced
pancreatic neuroendocrine tumors: latest evidence and clinical potential. 
formation during treatment with sunitinib malate: case report. BMC 
endothelial cell functions and lymph node metastasis in a breast cancer
model through inhibition of vascular endothelial growth factor receptor 3. 
13. Ballas MS, Chachoua A. Rationale for targeting VEGF, FGFR, and PDGF for
14. Pal SK, Figlin RA, Yu H. Deciphering the anticancer mechanisms of
15. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic
role of integrating this novel treatment modality with chemoradiation
17. Chen YY, Yeh CN, Cheng CT, et al. Sunitinib for Taiwanese patients
with gastrointestinal stromal tumor after imatinib treatment failure or
18. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of
platelet-derived growth factor receptor alpha (PDGFRα) in gastrointestinal
19. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast
20. Ferguson T, Gore M. Which patients with renal cancer may benefit
administration in advanced renal cell carcinoma patients: a single cancer
22. Zama IN, Hutson TE, Elson P, et al. Sunitinib rechallenge in metastatic
5400–5406.
23. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon
115–124.
of life in patients with metastatic renal cell carcinoma treated with
sunitinib vs interferon-alpha in a phase III trial: final results and geographical
25. Blagoev KB, Wilkerson J, Stein WD, Motzer RJ, Bates SE, Fojo AT. 
Effect of sunitinib (SU) administration on post-treatment survival in patients
with metastatic renal cell carcinoma (mRCC) treated on the
upfront randomized phase III trial of sunitinib or interferon alfa (IFN). 
ors and outcome of sunitinib treatment in patients with metastatic renal

27. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib
in patients with metastatic non-clear cell renal cell carcinoma. Invest New 
efficacy in patients with metastatic renal cell carcinoma treated with
29. van der Veldt AA, Meijerink MR, van den Eertwegh AJ, Haanen JB, 
Boven E. Choi response criteria for early prediction of clinical outcome
in patients with metastatic renal cell cancer treated with sunitinib. 
Korean patients with advanced renal cell carcinoma: high incidence of
toxicity leads to frequent dose reduction. Jpn J Clin Oncol. 2010;40(10): 
980–985.
2012;118(7):1868–1876.
sunitinib may improve the response rate, progression free survival and
overall survival of patients with bone metastases from renal cell carcinoma. 
33. Tielen R, Verhoef C, van Coevorden F, et al. Surgery after treat-
ment with imatinib and/or sunitinib in patients with metastasized
2012;10:111.


54. Raymond E, Niccoli P, Raoul J, et al. Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BIRC) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET). *J Clin Oncol.* 2011;29 Suppl 4:2492.


